Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving LENZ Therapeutics, Inc. following a significant drop in its stock price due to adverse event reports related to its product [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of LENZ Therapeutics, Inc. and is looking into whether the company and its officers or directors have engaged in fraudulent activities [1]. - The investigation was prompted by a report of a retinal tear associated with LENZ's VIZZ eye drop, which was recorded in the FDA's adverse event reporting systems [3]. Group 2: Stock Price Impact - Following the adverse event report on December 12, 2025, LENZ's stock price decreased by $6.36 per share, representing a decline of 25.96%, closing at $18.14 per share on that date [3]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4].

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ: INSM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Insmed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On December 17 ...

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cogent Communications Holdings, Inc. (“Cogent” or the “Company”) (NASDAQ: CCOI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Cogent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action ...

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ETHZilla Corporation (“ETHZilla” or the “Company”) (NASDAQ: ETHZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether ETHZilla and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Decembe ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Bgin Blockchain Limited ("Bgin†or the "Company†) (NASDAQ: BGIN) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BGIN BLOCKCHAIN LIMITED (BGIN), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights. ...

SAN DIEGO, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving RH (NYSE: RH) focused on whether RH as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the RH investigation or if you are an RH investor who suffered a loss and would like to learn more, you can provide your informatio ...

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Bgin Blockchain Limited for potential violations of federal securities laws following its Initial Public Offering on October 21, 2025 [1] Group 1 - The investigation is on behalf of investors who may have lost money on Bgin Blockchain Limited [1] - The company is listed on NASDAQ under the ticker symbol BGIN [1]

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities [3]. Group 2: Company Performance and Stock Impact - Alexandria Real Estate, a real estate investment trust focused on life science industries, reported lower occupancy rates and slower leasing activity, leading to a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property [4][5]. - On October 27, 2025, the company announced disappointing 3Q 2025 results and reduced guidance for the fiscal year, causing its stock to drop by $14.93 per share, or over 19%, from $77.87 to $62.94 [6]. - The company indicated that the Long Island City property was not a viable life science destination that could scale, contributing to the impairment charges [6]. Group 3: Legal Representation - Bleichmar Fonti & Auld LLP, the law firm representing the plaintiffs, has a strong track record in securities class actions and has recovered significant amounts for investors in previous cases [8]. - The firm operates on a contingency fee basis, meaning there are no upfront costs for shareholders [7].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025, following this announcement [8].

New York, New York--(Newsfile Corp. - December 29, 2025) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws. If you invested in Stride, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/stride ...